Novogen Limited is engaged in pharmaceutical research and development, and marketing of consumer healthcare products. The Company has three segments: Drug Development, Oncology Drug Program, Consumer Business and Wound Healing. Drug Development includes the discovery of new compounds and the early stage screening for bioactivity of such compounds through both in vivo and in vitro testing. Oncology Drug Program involves the development of selected oncology drug candidates, which have indicated bioactivity against cancer cells through clinical trial programs to assess safety and efficacy. The Company�s clinical development program run through Novogen�s subsidiaries Marshall Edwards, Inc. (MEI) and Glycotex, Inc. (Glycotex). In December 2012, the Company acquired 10% of Triaxial Pharmaceuticals Pty Ltd. In February 2013, it completed its exchanged offer through which it was to split off its 63.5% interest in MEI Pharma, Inc.